Assistance Publique Hopitaux De Paris

At Assistance Publique Hopitaux De Paris, the Hematology program includes a strong focus on hemic and lymphatic diseases and neoplasms, especially acute myeloid leukemia, myelodysplastic syndrome, multiple myeloma, and several forms of lymphoma. These studies are designed to test new treatment approaches, improve disease control, and better support patients whose cancers have returned or no longer respond to standard care.

• New therapies for acute myeloid leukemia and myelodysplastic syndrome in difficult-to-treat settings
• CAR-T and other cell therapy approaches for blood cancers
• Combination strategies for lymphoma, including follicular lymphoma, diffuse large B-cell lymphoma, and Richter syndrome
• Studies in multiple myeloma aimed at improving response after transplant or at diagnosis

This research reflects a broad effort to advance blood cancer treatment through both innovative immunotherapy and improved treatment combinations.

The site also has active research in skin and connective tissue diseases and immune system diseases, with trials in atopic dermatitis, hidradenitis suppurativa, prurigo nodularis, generalized pustular psoriasis, Netherton syndrome, rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis, and idiopathic inflammatory myopathy. The purpose of these studies is to evaluate whether new treatments can reduce symptoms, improve skin healing, and provide better long-term control of chronic inflammatory conditions.

• Testing new options for moderate-to-severe atopic dermatitis and related skin disorders
• Research on hidradenitis suppurativa, psoriasis, and prurigo nodularis to improve symptom relief
• Studies in autoimmune conditions such as rheumatoid arthritis, lupus, and systemic sclerosis
• Evaluation of therapies for rare inherited skin disease, including Netherton syndrome

This portfolio highlights a patient-centered effort to improve both comfort and disease control in chronic inflammatory and dermatologic disorders.

Clinical research at this Paris site covers several neoplasms, including melanoma, prostate cancer, esophageal carcinoma, gastroesophageal adenocarcinoma, renal cell carcinoma, and colorectal cancer. The trials are mainly focused on testing new treatment combinations, comparing approaches after surgery, and improving survival for patients with advanced or high-risk disease.

• Immunotherapy studies in melanoma and other advanced solid tumors
• Treatment research for prostate cancer, including high-risk and metastatic disease
• Combination therapy trials in esophageal and gastroesophageal cancers
• Studies aiming to improve outcomes in renal and colorectal cancer

Overall, the oncology program is centered on evaluating whether newer therapies can extend survival and reduce recurrence in difficult solid tumors.

Another major area of work involves bacterial infections and mycoses and virus diseases, with studies in HIV-1 infection, COVID-19, monkeypox, community-acquired pneumonia, and progressive multifocal leukoencephalopathy. These trials are designed to assess prevention strategies, improve antiviral treatment, and determine whether new approaches can shorten illness or improve recovery in vulnerable patients.

• Research on HIV treatment and prevention, including regimen switching and first-line therapy
• Studies in COVID-19 and other viral infections to improve antiviral effectiveness
• Clinical trials for monkeypox and progressive multifocal leukoencephalopathy
• Hospital-based research in community-acquired pneumonia to refine antibiotic use

These studies show a broad commitment to better infection control, especially for patients with complex or weakened immune systems.

The research program also includes studies in hematopoietic stem cell transplantation, essential thrombocythaemia, and other congenital, hereditary, and neonatal diseases. At Assistance Publique Hopitaux De Paris, investigators are examining ways to prevent transplant complications, support blood recovery, and improve care for patients with rare or hard-to-treat blood conditions.

• Strategies to reduce complications after allogeneic stem cell transplantation
• Treatments for essential thrombocythaemia and related blood count disorders
• Studies aimed at improving recovery and survival after transplantation
• Supportive research for rare hematologic and inherited conditions

This work complements the site’s broader hematology expertise by focusing on safer recovery and better long-term outcomes.